GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marvel Biosciences Corp (TSXV:MRVL) » Definitions » ROIC %

Marvel Biosciences (TSXV:MRVL) ROIC % : 0.00% (As of Oct. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Marvel Biosciences ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Marvel Biosciences's annualized return on invested capital (ROIC %) for the quarter that ended in Oct. 2024 was 0.00%.

As of today (2025-03-02), Marvel Biosciences's WACC % is 5.35%. Marvel Biosciences's ROIC % is 0.00% (calculated using TTM income statement data). Marvel Biosciences earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Marvel Biosciences ROIC % Historical Data

The historical data trend for Marvel Biosciences's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marvel Biosciences ROIC % Chart

Marvel Biosciences Annual Data
Trend Jul20 Jul21 Jul22 Jul23 Jul24
ROIC %
- - - - -

Marvel Biosciences Quarterly Data
Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Marvel Biosciences's ROIC %

For the Biotechnology subindustry, Marvel Biosciences's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Marvel Biosciences's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marvel Biosciences's ROIC % distribution charts can be found below:

* The bar in red indicates where Marvel Biosciences's ROIC % falls into.



Marvel Biosciences ROIC % Calculation

Marvel Biosciences's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Jul. 2024 is calculated as:

ROIC % (A: Jul. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Jul. 2023 ) + Invested Capital (A: Jul. 2024 ))/ count )
=0 * ( 1 - 0% )/( (0 + 0)/ 2 )
=0/0
= %

where

Marvel Biosciences's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Oct. 2024 is calculated as:

ROIC % (Q: Oct. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jul. 2024 ) + Invested Capital (Q: Oct. 2024 ))/ count )
=-0.928 * ( 1 - 0% )/( (0 + 0)/ 2 )
=-0.928/0
= %

where

Note: The Operating Income data used here is four times the quarterly (Oct. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Marvel Biosciences  (TSXV:MRVL) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Marvel Biosciences's WACC % is 5.35%. Marvel Biosciences's ROIC % is 0.00% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Marvel Biosciences ROIC % Related Terms

Thank you for viewing the detailed overview of Marvel Biosciences's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Marvel Biosciences Business Description

Traded in Other Exchanges
Address
505 - 8th Avenue SW, Suite 420, Calgary, AB, CAN, T2P1G2
Marvel Biosciences Corp is a life sciences company focused on the discovery and development of a synthetic derivative compound of a known drug. It has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer's, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.
Executives
Joseph Roderick Matheson Director, Senior Officer
Neil Allan Johnson Director
Jacqueline Groot Senior Officer